Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul;14(1):73-78.
doi: 10.3892/ol.2017.6117. Epub 2017 May 4.

Treatment outcome analysis of chemotherapy combined with modulated electro-hyperthermia compared with chemotherapy alone for recurrent cervical cancer, following irradiation

Sun Young Lee  1   2 , Na Ri Lee  2   3 , Dong-Hyu Cho  2   4 , Jung Soo Kim  1   2
Affiliations

Treatment outcome analysis of chemotherapy combined with modulated electro-hyperthermia compared with chemotherapy alone for recurrent cervical cancer, following irradiation

Sun Young Lee et al. Oncol Lett. 2017 Jul.

Abstract

The survival of patients with recurrent cervical cancer following irradiation remains poor. Chemotherapy combined with hyperthermia has been demonstrated to improve the response rate. The present study was performed to evaluate the effect of modulated electro-hyperthermia combined with conventional chemotherapy compared with chemotherapy alone on recurrent cervical cancer previously treated with irradiation. A total of 20 patients were treated with chemotherapy alone, and 18 were treated with chemotherapy combined with modulated electro-hyperthermia. A single patient was treated with chemo-radiotherapy as primary treatment and then relapsed; the tumor was inoperable and radio-refractory upon recurrence. Local metastases, including metastasis of the para-aortic lymph nodes and adjacent pelvic lymph nodes were included, but distant metastases were excluded. Modulated electro-hyperthermia was performed three times per week beginning at chemotherapy initiation, and patients underwent a total of 36 sessions. The overall response (complete remission + partial remission + stable disease/progressive disease) to treatment was significantly greater in the group of patients who underwent chemotherapy combined with modulated electro-hyperthermia (P=0.0461), and at the evaluation conducted at the last follow-up visit, the response rate was significantly higher (P=0.0218). Additionally, severe complications were not reported. In the present study, of patients with recurrent cervical cancer previously treated with irradiation, the overall response rate for patients treated with chemotherapy combined with modulated electro-hyperthermia was significantly greater than that for those treated with chemotherapy alone.

Keywords: chemotherapy alone; concurrent chemo-modulated electro-hyperthermia; recurrent cervical cancer; treatment outcome.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overall survival of the patients treated with chemotherapy alone compared with those subjected to CT combined with mEHT groups. CT combined with mEHT did not significantly increase the overall survival rate (P=0.235). CT, chemotherapy; mEHT, modulated electro-hyperthermia.
Figure 2.
Figure 2.
Body temperature and abdominal skin surface temperature underneath the electrode, during modulated electro-hyperthermia.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. International Agency for Research on Cancer, corp-author. Latest world cancer statistics. IARC; Lyon: 2013. World Health Organization.
    1. American Society of Clinical Oncology (ASCO), corp-author http://www.cancer.net/cancer-types/cervical-cancer/statistics Cervical cancer: Statistics.
    1. Korean statistical information service, corp-author. Statistics Korea. http://kosis.kr Statistics Korea, Daejeon. 2012
    1. Seol HJ, Ki KD, Lee JM. Epidemiologic characteristics of cervical cancer in Korean women. J Gynecol Oncol. 2014;25:70–74. doi: 10.3802/jgo.2014.25.1.70. - DOI - PMC - PubMed
    1. Kuo DY, Blank SV, Christos PJ, Kim M, Caputo TA, Pothuri B, Hershman D, Goldman N, Ivy PS, Runowicz CD, et al. Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: A New York cancer consortium study. Gynecol Oncol. 2010;116:442–446. doi: 10.1016/j.ygyno.2009.10.082. - DOI - PMC - PubMed